Xiaoyi Guo

机构：Peking University, National Medical Products Administration, Peking University Cancer Hospital, Shanghai Traditional Chinese Medicine Hospital, Ministry of Education, Wuxi Taihu Hospital

发表论文 64 篇 · 总被引 1271 次 · h-index 20

代表论文

• High in-vivo stability in preclinical and first-in-human experiments with [18F]AlF-RESCA-MIRC213: a 18F-labeled nanobody as PET radiotracer for diagnosis of HER2-positive cancers (2022 · European Journal of Nuclear Medicine and Molecular Imaging · 被引 53)
• 68Ga-labeled ODAP-Urea-based PSMA agents in prostate cancer: first-in-human imaging of an optimized agent (2021 · European Journal of Nuclear Medicine and Molecular Imaging · 被引 37)
• HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking (2022 · Theranostics · 被引 33)
• Comparison of renal clearance of [18F]AlF-RESCA-HER2-BCH and [18F]AlF-NOTA-HER2-BCH in mice and breast cancer patients (2023 · European Journal of Nuclear Medicine and Molecular Imaging · 被引 28)
• The Value of 18F-FDG PET/CT and Abdominal PET/MRI as a One-Stop Protocol in Patients With Potentially Resectable Colorectal Liver Metastases (2021 · Frontiers in Oncology · 被引 23)
• Copper-64 Based PET-Radiopharmaceuticals: Ways to Clinical Translational (2024 · Seminars in Nuclear Medicine · 被引 17)